Please use this identifier to cite or link to this item: https://doi.org/10.3201/eid2607.190539
DC FieldValue
dc.titleBurden and Cost of Hospitalization for Respiratory Syncytial Virus in Young Children, Singapore
dc.contributor.authorTam, C.C.
dc.contributor.authorTam, C.C.
dc.contributor.authorTam, C.C.
dc.contributor.authorTam, C.C.
dc.contributor.authorYeo, K.T.
dc.contributor.authorYeo, K.T.
dc.contributor.authorTee, N.
dc.contributor.authorTee, N.
dc.contributor.authorLin, R.
dc.contributor.authorMak, T.M.
dc.contributor.authorThoon, K.C.
dc.contributor.authorThoon, K.C.
dc.contributor.authorThoon, K.C.
dc.contributor.authorJit, M.
dc.contributor.authorYung, C.F.
dc.contributor.authorYung, C.F.
dc.contributor.authorYung, C.F.
dc.date.accessioned2021-08-18T03:59:31Z
dc.date.available2021-08-18T03:59:31Z
dc.date.issued2020
dc.identifier.citationTam, C.C., Tam, C.C., Tam, C.C., Tam, C.C., Yeo, K.T., Yeo, K.T., Tee, N., Tee, N., Lin, R., Mak, T.M., Thoon, K.C., Thoon, K.C., Thoon, K.C., Jit, M., Yung, C.F., Yung, C.F., Yung, C.F. (2020). Burden and Cost of Hospitalization for Respiratory Syncytial Virus in Young Children, Singapore. Emerging Infectious Diseases 26 (7) : 1489-1496. ScholarBank@NUS Repository. https://doi.org/10.3201/eid2607.190539
dc.identifier.issn10806040
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/197698
dc.description.abstractRespiratory syncytial virus (RSV) is the most common cause of pediatric acute lower respiratory tract infection worldwide. Detailed data on the health and economic burden of RSV disease are lacking from tropical settings with year-round RSV transmission. We developed a statistical and economic model to estimate the annual incidence and healthcare cost of medically attended RSV disease among young children in Singapore, using Monte Carlo simulation to account for uncertainty in model param-eters. RSV accounted for 708 hospitalizations in children <6 months of age (33.5/1,000 child-years) and 1,096 in children 6-29 months of age (13.2/1,000 child-years). The cost of hospitalization was SGD 5.7 million (US $4.3 million) at 2014 prices; patients bore 60% of the cost. RSV-associated disease burden in tropical settings in Asia is high and comparable to other settings. Further work incorporating efficacy data from ongoing vaccine trials will help to determine the potential cost-effectiveness of different vaccination strategies. � 2020 Centers for Disease Control and Prevention (CDC). All rights reserved.
dc.publisherCenters for Disease Control and Prevention (CDC)
dc.sourceScopus OA2020
dc.typeArticle
dc.contributor.departmentSAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
dc.contributor.departmentDEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
dc.contributor.departmentPAEDIATRICS
dc.description.doi10.3201/eid2607.190539
dc.description.sourcetitleEmerging Infectious Diseases
dc.description.volume26
dc.description.issue7
dc.description.page1489-1496
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3201_eid2607_190539.pdf1.33 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.